December 21, 2016 / 6:23 AM / 8 months ago

BRIEF-Kiadis Pharma provides update on second dose trial with ATIR101

Dec 21 (Reuters) - Kiadis Pharma Nv :

* Kiadis Pharma provides update on second dose trial (CR-AIR-008) with ATIR101

* No patient suffered from grade III/IV graft-versus-host-disease (GVHD) upon infusion of first dose

* Company will continue its CR-AIR-008 trial, treating patients with a single dose of ATIR101 according to recommendation of independent data monitoring committee

* In Phase II trial safety and efficacy of a second dose of ATIR101 is being tested in patients to investigate product flexibility in administering a further dose of ATIR101

* Fifteen patients have been recruited into trial to date of which ten have received one or two doses of ATIR101 after their haploidentical stem cell transplantation Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below